AKT1 Q79K

CI-VAR-00003594Explore in graph →NP_001014432.1:p.Gln79LysNM_001014432.1:c.235C>AClinVar 376168 CIViC 169 rs1057519804

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma3
AKT1 Q79K	Dabrafenib	Predictive	C	Supports Resistance	4	accepted	EID6260 In a retrospective study of 44 relapsed melanoma patients with BRAF V600E/K (known BRAF inhibitor sensitizing mutations), AKT1 Q79K was associated with acquired resistance to BRAF inhibitor (dabrafeni… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
AKT1 Q79K	Vemurafenib	Predictive	D	Supports Resistance	4	accepted	EID439 The AKT1 Q79K mutation has been shown to confer resistance to BRAF inhibitors (vemurafenib) in melanoma cell line M229. PMID 24265152 · Shi et al., 2014 · Open in CIViC	civic
AKT1 Q79K	Vemurafenib

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.